Searchable abstracts of presentations at key conferences in endocrinology

ea0063p235 | Pituitary and Neuroendocrinology 1 | ECE2019

No central adrenal insufficiency found in adults with prader-willi syndrome tested by multiple dose metyrapone test

Rosenberg Anna , Pellikaan Karlijn , Davidse Kirsten , Donze Stephany , Hokken-Koelega Anita , de Graaff Laura

Introduction: Individuals with Prader-Willi syndrome (PWS) have hypothalamic dysfunction, with deficiencies of several hypothalamic-pituitary axes. Prevalence of central hypogonadism, hypothyroidism and growth hormone deficiency are increased in comparison with non-PWS individuals. Central adrenal insufficiency (CAI) has also been reported in PWS. Several studies, using different testing modalities, have reported strikingly differing prevalences of CAI in PWS, ranging from 0% ...

ea0070aep400 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Systematic screening reveals large number of undiagnosed and untreated cardiovascular risk factors in adults with prader-willi syndrome

Pellikaan Karlijn , Rosenberg Anna , Davidse Kirsten , Jan Van der Lely Aart , De Graaff Laura

Introduction: Prader-Willi syndrome (PWS) is a complex hypothalamic disorder, combining hypotonia, intellectual disability (ID), pituitary hormone deficiencies and hyperphagia. In PWS, up to 3% of patients die every year. In half of the patients, the cause of death is obesity related and / or of cardiovascular origin. Obesity is caused by hyperphagia combined with a low energy expenditure. Untreated hormone deficiencies like hypogonadism and hypothyroidism can cause low muscle...

ea0056p825 | Pituitary - Clinical | ECE2018

Iceberg alert: undetected health problems in adults with Prader-Willi syndrome – multidisciplinary care could prevent ‘unexplained deaths’

Pellikaan Karlijn , Rosenberg Anna , Baan Janneke , Davidse Kirsten , de Graaff Laura

Introduction: A yearly mortality rate of 4% among young adult patients is unacceptable in any patient population. Nevertheless, in Prader-Willi syndrome (PWS), up to 4% of young patients die every year and this situation has been going on for decades. PWS is a complex hypothalamic disorder, combining hypotonia, intellectual disability (ID), pituitary hormone deficiencies and hyperphagia. Due to this lack of satiety, patients can literally eat themselves to death: overeating ca...

ea0073aep493 | Pituitary and Neuroendocrinology | ECE2021

Growth hormone treatment for adults with Prader-Willi syndrome: A meta-analysis

Rosenberg Anna , Passone Caroline , Pellikaan Karlijn , Damiani Durval , Aart Jan Van der Lely , Polak Michel , Bernardo Wanderley , Graaff Laura De

BackgroundFeatures of Prader-Willi syndrome (PWS) overlap with features of growth hormone (GH) deficiency, like small hands and feet, short stature, increased body fat and low muscle mass and strength. In children with PWS, GH treatment improves physical health, cognition and quality of life (QoL). GH treatment is standard of care in PWS children, but in adults this is not the case. A systematic review and meta-analysis was conducted to provide a concise...

ea0073aep681 | Thyroid | ECE2021

Thyroid function in adults with Prader-Willi syndrome.

Pellikaan Karlijn , Snijders Fleur , Rosenberg Anna , Sjoerd van den Berg , Aart Jan Van der Lely , De Graaff Laura

IntroductionPrader-Willi syndrome (PWS) is a complex genetic syndrome in which hypothalamic dysfunction leads to hyperphagia and pituitary hormone deficiencies (PHD), among others. The majority of patients have intellectual disability (ID) and use of psychotropic drugs is frequent. Due to hypotonia and the low muscle mass associated with the syndrome, adults with PWS have a low basal metabolic rate (BMR). Combined with hyperphagia, this results in high r...

ea0081p155 | Pituitary and Neuroendocrinology | ECE2022

Genetic subtype differences in relation to health problems among adults with Prader-Willi syndrome

Rosenberg Anna , Pellikaan Karlijn , Wellink Charlotte , Tellez Garcia Juan , van Abswoude Denise , van Zutven Laura , Bruggenwirth Hennie , Resnick James , Jan Van der Lely Aart , De Graaff Laura

Background: Prader-Willi syndrome (PWS) is a complex rare genetic disorder associated with hypothalamic dysfunction, pituitary hormone deficiencies, hyperphagia and (morbid) obesity. PWS is caused by loss of expression of paternally expressed genes on chromosome 15q11.2-q13. The most common genetic mechanisms leading to PWS are paternal deletion (DEL) and maternal uniparental disomy (mUPD). DELs can be subdivided in type 1 and (smaller) type 2 deletions (DEL-1, DEL-2). Most re...

ea0063gp175 | Obesity (1) | ECE2019

Normal IGF-bioactivity and low free IGF-I in patients with Prader-Willi syndrome with high total serum IGF-I: immunoreactive IGF-I concentrations poorly reflect IGF bio-activity and bio-availability

Pellikaan Karlijn , Elizabeth Melitza , Donze Stephany , van den Berg Sjoerd , van Doorn Jaap , Peeters Robin P , Hokken-Koelega Anita CS , de Graaff Laura CG

Introduction: Prader-Willi Syndrome (PWS) is a complex syndrome including hyperphagia, pituitary hormone deficiencies, low muscle mass and cognitive impairment. Treatment with recombinant Growth Hormone (GH) has beneficial effects on body composition, physical performance, cognition, psychomotor development, respiratory function, and quality of life of patients with PWS. GH treatment has a narrow therapeutic range. Clinicians measure serum immunoreactive Insulin-like Growth Fa...